MCID: NRN004
MIFTS: 58

Neuroendocrine Tumor

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 72 49 14
Neuroendocrine Neoplasm 12 49 28
Neuroendocrine Tumors 51 41 69
Carcinoma, Neuroendocrine 41 69
Neuroendocrine Carcinoma 12 14
Neuroendocrine Neoplasia 49
Carcinoma Neuroendocrine 51
Neuroendocrine Cancer 72

Classifications:



External Ids:

Disease Ontology 12 DOID:169 DOID:1800
ICD10 32 D3A.8
ICD9CM 34 209 209-209.99
NCIt 46 C3809 C3773

Summaries for Neuroendocrine Tumor

Disease Ontology : 12 An endocrine gland cancer that has material basis in neuroendocrine cells.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine neoplasm, is related to gastric neuroendocrine tumor and gastrointestinal neuroendocrine tumor. An important gene associated with Neuroendocrine Tumor is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Afinitor and Sutent have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 72 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 402)
# Related Disease Score Top Affiliating Genes
1 gastric neuroendocrine tumor 34.0 CALCA GAST
2 gastrointestinal neuroendocrine tumor 34.0 CHGA SYP
3 esophageal neuroendocrine tumor 33.7 CHGA NCAM1 SYP
4 insulinoma 32.8 CHGA INSM1 MEN1 SST
5 gastrinoma 32.5 CHGA GAST MEN1 SST
6 duodenal gastrinoma 32.4 GAST GRP MEN1
7 gastric gastrinoma 32.2 ENO2 GAST
8 gastric neuroendocrine neoplasm 32.1 CHGA GAST SST
9 von hippel-lindau syndrome 32.1 CHGA CHGB MEN1 SDHD
10 duodenal somatostatinoma 32.0 CALCA ENO2 SST
11 goblet cell carcinoid 31.7 CHGA ENO2 GAST KRT20
12 pancreatic islet cell tumors 31.5 CALCA GAST MEN1 NTS SST
13 pancreatic cancer 31.4 CHGA GAST GRP MEN1 NTS SST
14 multiple endocrine neoplasia 31.2 CALCA CHGA MEN1
15 acromegaly 30.6 MEN1 SST SSTR2
16 pituitary adenoma 30.3 MEN1 SST SSTR2
17 adenoma 30.2 KRT7 MEN1 SST SSTR2
18 glucagonoma 30.2 CHGA CHGB SST
19 multiple endocrine neoplasia, type i 30.2 CHGA GAST MEN1 SDHD SST SYP
20 neurofibromatosis, type iv, of riccardi 30.0 MEN1 SDHD SST
21 pheochromocytoma 30.0 ASCL1 CALCA CHGA CHGB ENO2 MEN1
22 ectopic cushing syndrome 30.0 MEN1 SST SYP
23 pulmonary large cell neuroendocrine carcinoma 29.9 CHGA ENO2 SYP
24 duodenal ulcer 29.9 GAST GRP SST
25 gastrointestinal stromal tumor 29.8 CHGA ENO2 SDHD SYP
26 somatostatinoma 29.8 CALCA CHGA ENO2 SST
27 paraganglioma 29.7 CALCA CHGA ENO2 SDHD SST SYP
28 carcinoid syndrome 29.6 CALCA CHGA ENO2 MEN1 NTS SST
29 vipoma 29.5 CALCA CHGA GAST NTS SST
30 meningioma, familial 29.3 MEN1 NCAM1 SST SSTR2 SYP
31 cystadenoma 29.0 CHGA KRT20 KRT7 SYP
32 neuroblastoma 28.9 ASCL1 ENO2 NCAM1 NTS SYP
33 sclerosing hemangioma 28.7 CHGA ENO2 KRT7 NKX2-1 SYP
34 renal cell carcinoma, nonpapillary 28.5 ENO2 KRT20 KRT7 NKX2-1
35 thyroid carcinoma, familial medullary 28.4 CALCA CHGA ENO2 GAST GRP MEN1
36 teratoma 28.3 ENO2 KRT20 KRT7 NKX2-1 SYP
37 cystic teratoma 28.2 ENO2 KRT20 KRT7 NKX2-1 SYP
38 horseshoe kidney 28.1 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
39 merkel cell carcinoma 27.1 CHGA ENO2 KRT20 KRT7 NCAM1 NKX2-1
40 large cell neuroendocrine carcinoma 27.0 ASCL1 CHGA ENO2 KRT20 KRT7 NCAM1
41 small cell carcinoma 26.7 ASCL1 CALCA CHGA ENO2 KRT20 KRT7
42 lung cancer 26.6 ASCL1 CHGA ENO2 GRP KRT20 KRT7
43 small cell cancer of the lung 25.9 ASCL1 CALCA CHGA ENO2 GAST GRP
44 pancreatic neuroendocrine tumor 12.4
45 pulmonary neuroendocrine tumor 12.3
46 gastro-enteropancreatic neuroendocrine tumor 12.3
47 laryngeal neuroendocrine tumor 12.1
48 anal neuroendocrine tumor 12.1
49 neuroendocrine tumor of the appendix 12.1
50 ileal neuroendocrine tumor 12.0

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.85 SSTR2 SYP ASCL1 ENO2 GRP NCAM1
2 nervous system MP:0003631 9.73 SYP ASCL1 CHGB ENO2 INSM1 MEN1
3 no phenotypic analysis MP:0003012 9.17 ASCL1 CHGA CHGB INSM1 NKX2-1 NTS

Drugs & Therapeutics for Neuroendocrine Tumor

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009
2
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
5
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
10
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
12
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 6400441 383414
13
Pancrelipase Approved, Investigational Phase 4,Phase 1,Phase 2 53608-75-6
14
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
15
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
16
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
17
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
18
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
19
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 110942-02-4, 85898-30-2
20 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
23
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
24
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 44462760 44516822
25
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
26
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
27
Gefitinib Approved, Investigational Phase 4,Phase 2 184475-35-2 123631
28
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 5330286 11431660 5005498
29
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
30
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
31
Aminolevulinic acid Approved Phase 4 106-60-5 137
32
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
33
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Olaparib Approved Phase 4 763113-22-0 23725625
35 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
36
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
37
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
38 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
40 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
43 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2464)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
5 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
6 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
7 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
8 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
9 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
10 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
11 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
12 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
13 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
14 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
15 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
16 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
17 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
18 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
19 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
20 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
21 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
22 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
23 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
24 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
25 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
26 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
27 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
28 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
29 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
30 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
31 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
32 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
33 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
34 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
35 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
36 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
37 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
38 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
39 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
40 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
41 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
42 Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor Unknown status NCT02330497 Phase 3
43 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
44 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
45 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
46 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
47 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
48 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
49 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
50 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3

Search NIH Clinical Center for Neuroendocrine Tumor

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

# Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 28

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

38
Lung, Brain, Liver, Thyroid, Skin, Kidney, Lymph Node

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1227)
# Title Authors Year
1
Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to<sup>177</sup>Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. ( 29331677 )
2018
2
Fine-needle aspiration of a pancreatic neuroendocrine tumor with prominent rhabdoid features. ( 29359517 )
2018
3
Underwater endoscopic mucosal resection: a new endoscopic method for resection of rectal neuroendocrine tumor grade 1 (carcinoid) a8oa8810a88mm in diameter. ( 29344571 )
2018
4
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. ( 29122330 )
2018
5
Case Report of a Small Gastric Neuroendocrine Tumor in a Deep Layer of Submucosa With Diagnosis by Endoscopic Ultrasound-Guided Fine-Needle Aspiration and Treatment With Laparoscopic and Endoscopic Cooperative Surgery. ( 29371789 )
2018
6
A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes. ( 29270782 )
2018
7
A Rare Case of Synchronous Papillary Microcarcinoma and Metastatic Neuroendocrine Tumor of Unknown Primary. ( 29430119 )
2018
8
Incidental Detection of Asymptomatic Brain Metastases on<sup>18</sup>F-fluoride Positron Emission Tomography/Computed Tomography and<sup>68</sup>Ga DOTANOC Positron Emission Tomography/Computed Tomography in a Patient with Concomitant Breast Carcinoma and a Pancreatic Neuroendocrine Tumor. ( 29398971 )
2018
9
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report. ( 29326972 )
2018
10
Simultaneous Glucagon and Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors in a Patient With Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review. ( 29232343 )
2018
11
Gastric neuroendocrine tumor arising from heterotopic pancreas. ( 29218566 )
2018
12
Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor. ( 29404984 )
2018
13
Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. ( 29448303 )
2018
14
Letter to the editors regarding: genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution. ( 29338880 )
2018
15
Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. ( 29107104 )
2018
16
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor. ( 29375864 )
2018
17
A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation. ( 29432346 )
2018
18
Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors. ( 29150024 )
2018
19
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. ( 29330294 )
2018
20
Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. ( 29140113 )
2018
21
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). ( 29330208 )
2018
22
Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). ( 29325706 )
2018
23
Cystic pancreatic neuroendocrine tumor. Pancreatic endocrine or neuroendocrine tumor. Endoscopic ultrasonography. ( 29313698 )
2018
24
Gastric neuroendocrine tumor with hypergastrinemia following type B chronic atrophic gastritis: a case report. ( 28163290 )
2017
25
Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome-associated multifocal, non-functioning pancreatic neuroendocrine tumor: A case report. ( 28589571 )
2017
26
Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. ( 29040196 )
2017
27
Multiple Neuroendocrine Tumors in Stomach and Duodenum in a Multiple Endocrine Neoplasia Type 1 Patient. ( 29268593 )
2017
28
Renal Cell Carcinoma and a Pancreatic Neuroendocrine Tumor: A Coincidence or Instance of Von Hippel-Lindau Disease? ( 28794363 )
2017
29
Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. ( 28787330 )
2017
30
GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE. ( 29257854 )
2017
31
Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. ( 28849340 )
2017
32
Pancreatic neuroendocrine tumor with complete replacement of the pancreas by serous cystic neoplasms in a patient with von Hippel-Lindau disease: a case report. ( 28948530 )
2017
33
The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. ( 28082438 )
2017
34
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. ( 28642335 )
2017
35
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. ( 28597868 )
2017
36
68Ga-DOTATATE PET/CT in Primary Hepatic Neuroendocrine Tumor. ( 28005645 )
2017
37
Correction: Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. ( 28772359 )
2017
38
Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. ( 29142475 )
2017
39
Pancreatic Neuroendocrine Tumor Abnormally Secreting Procalcitonin. ( 27977635 )
2017
40
Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis. ( 29136022 )
2017
41
Diffuse Enlargement of the Pancreas: An Unusual Radiologic Presentation of a Pancreatic Neuroendocrine Tumor. ( 28624649 )
2017
42
CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses. ( 27864124 )
2017
43
Metastatic neuroendocrine tumor of the esophagus with features of medullary thyroid carcinoma. ( 28944148 )
2017
44
Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. ( 28334992 )
2017
45
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. ( 29212165 )
2017
46
Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report. ( 28068959 )
2017
47
Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma. ( 29152267 )
2017
48
An Elderly Man With Pancreatic Neuroendocrine Tumor and a Cavitary Right Upper Lobe Lung Mass. ( 28599947 )
2017
49
Neuroendocrine tumor of the extrahepatic bile duct: A case report. ( 28915429 )
2017
50
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. ( 28235630 )
2017

Variations for Neuroendocrine Tumor

Copy number variations for Neuroendocrine Tumor from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.55 CALCA ENO2 NCAM1 NKX2-1 SYP
2 11.23 ASCL1 NCAM1 SYP
3 9.8 GAST GRP

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 CALCA CHGA CHGB GAST GRP NCAM1
2 secretory granule GO:0030141 9.13 CHGA CHGB SCG2

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 CALCA CHGB MEN1 SCG2
2 neuropeptide signaling pathway GO:0007218 9.67 CALCA GRP SSTR2
3 positive regulation of neural precursor cell proliferation GO:2000179 9.51 ASCL1 INSM1
4 positive regulation of cAMP metabolic process GO:0030816 9.48 CALCA CHGA
5 forebrain neuron differentiation GO:0021879 9.46 ASCL1 NKX2-1
6 sympathetic ganglion development GO:0061549 9.4 ASCL1 INSM1
7 type B pancreatic cell differentiation GO:0003309 9.37 INSM1 MEN1
8 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 9.32 CHGA GRP
9 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.26 ASCL1 NKX2-1
10 regulation of receptor activity GO:0010469 9.17 CALCA CHGB GAST GRP NTS SCG2
11 noradrenergic neuron development GO:0003358 9.16 ASCL1 INSM1
12 adrenal chromaffin cell differentiation GO:0061104 8.96 ASCL1 INSM1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CALCA CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....